JP2023501111A5 - - Google Patents

Info

Publication number
JP2023501111A5
JP2023501111A5 JP2022523315A JP2022523315A JP2023501111A5 JP 2023501111 A5 JP2023501111 A5 JP 2023501111A5 JP 2022523315 A JP2022523315 A JP 2022523315A JP 2022523315 A JP2022523315 A JP 2022523315A JP 2023501111 A5 JP2023501111 A5 JP 2023501111A5
Authority
JP
Japan
Application number
JP2022523315A
Other languages
Japanese (ja)
Other versions
JP2023501111A (ja
JPWO2021094993A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/060692 external-priority patent/WO2021094993A1/en
Publication of JP2023501111A publication Critical patent/JP2023501111A/ja
Publication of JP2023501111A5 publication Critical patent/JP2023501111A5/ja
Publication of JPWO2021094993A5 publication Critical patent/JPWO2021094993A5/ja
Withdrawn legal-status Critical Current

Links

JP2022523315A 2019-11-14 2020-11-13 腸管における胆汁酸プロファイルを均衡させるための合成組成物 Withdrawn JP2023501111A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201901337 2019-11-14
DKPA201901337 2019-11-14
PCT/IB2020/060692 WO2021094993A1 (en) 2019-11-14 2020-11-13 Synthetic composition for balancing the bile acid profile in the intestine

Publications (3)

Publication Number Publication Date
JP2023501111A JP2023501111A (ja) 2023-01-18
JP2023501111A5 true JP2023501111A5 (https=) 2023-11-07
JPWO2021094993A5 JPWO2021094993A5 (https=) 2023-11-07

Family

ID=75912919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523315A Withdrawn JP2023501111A (ja) 2019-11-14 2020-11-13 腸管における胆汁酸プロファイルを均衡させるための合成組成物

Country Status (8)

Country Link
US (1) US20220378809A1 (https=)
EP (1) EP4058031A4 (https=)
JP (1) JP2023501111A (https=)
KR (1) KR20220101131A (https=)
CN (1) CN114728015A (https=)
BR (1) BR112022009214A2 (https=)
CA (1) CA3160629A1 (https=)
WO (1) WO2021094993A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
TW202126317A (zh) 2019-09-24 2021-07-16 美商普拉塔生技公司 用於治療發炎和免疫疾病之組成物和方法
WO2022026415A1 (en) * 2020-07-31 2022-02-03 Abbott Laboratories Method of preventing, reducing or delaying fatty liver disease
WO2022271729A1 (en) * 2021-06-21 2022-12-29 Pendulum Therapeutics, Inc. Compositions comprising microbes and methods of use and making thereof
CN115948273B (zh) * 2022-06-21 2023-07-18 合肥瀚微生物科技有限公司 治疗糖尿病及相关病症的两歧双歧杆菌
WO2024126578A1 (en) * 2022-12-13 2024-06-20 Dsm Ip Assets B.V. Synthetic composition comprising a human milk oligosaccharide for microbiota modulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2735108B1 (en) * 2011-07-22 2016-12-21 Telefonaktiebolaget LM Ericsson (publ) Radio base station, radio network node and methods therein for detecting a faulty antenna
AT515152B1 (de) * 2013-11-26 2015-12-15 Chemiefaser Lenzing Ag Verfahren zum Vorbehandeln von rückgewonnenen Baumwollfasern zur Verwendung bei der Herstellung von Formkörpern aus regenerierter Cellulose
EP3212197A4 (en) * 2014-10-29 2018-07-11 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
US11040049B2 (en) * 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US10987368B2 (en) * 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10751354B2 (en) * 2015-09-14 2020-08-25 Glycom A/S Synthetic composition for microbiota modulation
CN108348536B (zh) * 2015-11-17 2021-09-24 格礼卡姆股份公司 治疗抗生素相关性并发症的合成组合物
WO2017215721A1 (en) * 2016-06-15 2017-12-21 Glycom A/S Synthetic compositions comprising human milk oligosaccharides for use γν the prevention and treatment of disorders
US11278558B2 (en) * 2017-03-01 2022-03-22 Glycom A/S Synthetic composition for microbiota modulation
AU2018250337B2 (en) * 2017-04-07 2024-02-15 Children's Hospital Medical Center Treatment of inflammatory bowel diseases with 2'-fucosyllactose compounds
CN111587376A (zh) * 2017-09-13 2020-08-25 进化生物系统股份有限公司 哺乳动物婴儿的代谢组学修正
BR112020010843A2 (pt) * 2017-11-30 2020-11-10 Glycom A/S oligossacarídeos do leite humano e composições sintéticas desses para modulação da microbiota

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)